Publication: Glimepiride in type 2 diabetes mellitus Thai patients
Issued Date
2001-09-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0035705829
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.84, No.9 (2001), 1221-1228
Suggested Citation
Chaicharn Deerochanawong, Ampha Suthijumroon, Thep Himathongkam, Yupin Benjasuratawong, Veerasak Sarinnapakorn, Sunitaya Chandraprasert, Apichati Vichayanrat, Wannee Nitiyanant, Sompongse Suwanwalaikorn, Somboon Vongterapak Glimepiride in type 2 diabetes mellitus Thai patients. Journal of the Medical Association of Thailand. Vol.84, No.9 (2001), 1221-1228. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26727
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Glimepiride in type 2 diabetes mellitus Thai patients
Abstract
This study aimed to confirm the efficacy of glimepiride given once daily in the treatment of Thai type 2 diabetic patients and to find out the optimum dosage for Thai patients. The patients were enrolled at the diabetic clinics of 5 hospitals (Rajavithi, Chulalongkorn, Pramongkutklao, Siriraj and Theptarin Hospitals). All patients started glimepiride 1 mg once daily and escalated to 2, 3, 4 and until 6 mg every 4 weeks if fasting plasma glucose (FPG) exceeded 140 mg/dL. Subjects were 60 females and 29 males with an average age of 52.2 ± 10.0 years. Mean BMI was 25.5 ± 3.8 kg/m2. Fifty seven patients (64.0%) were drug naïve and thirty two patients (36.0%) had been previously treated with oral hypoglycemic agents. Seventy three per cent of the drug naïve and 37 per cent of the previously treated patients could be controlled with 1-2 mg of glimepiride once daily. At the twelfth week of treatment, mean fasting plasma glucose decreased from 224.6 to 156.6 mg/dL (30% reduction) and mean HbA1c decreased from 10.0 to 7.5 per cent (25% reduction). At the end of the study 49.4 per cent of the patients had HbA1c < 7.0 per cent, 21.3 per cent had HbA1c 7.0-8.0 per cent and 29.3 per cent had HbA1c > 8.0 per cent. Adverse events that were probably or possibly related to the drug were reported in 5 patients (5.6%). Three of them were hypoglycemia and two patients had skin rash. All hypoglycemic episodes were mild. Glimepiride was indicated to be safe. There were no clinically significant changes in clinical laboratory values, physical examinations and vital signs. In conclusion, glimepiride was efficacious and safe in type 2 diabetes Thai patients and 1-2 mg of glimepiride appeared to be a sufficient dose for most newly diagnosed type 2 diabetic patients.